Herring WL, Wittrup-Jensen V, Fox L. Value assessment of emerging treatments for nonalcoholic steatohepatitis: lessons from Institute for Clinical and Economic Review evaluations. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S76. doi: 10.1016/j.jval.2024.03.403
Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Herring WL, Gould IG, Wittrup-Jensen V, Kuti E, Mettam S, Ertle J, Wolowacz S. A conceptual model for the economic evaluation of emerging nonalcoholic steatohepatitis therapies: the impact of treatment efficacy profiles on health outcomes. Poster presented at the 2020 SMDM 18th Biennial European Conference (Conference cancelled); June 16, 2020.
Aggarwal K, Vredenburg M, Mladsi D, Barnett C. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 2020 AMCP Meeting (Conference cancelled); April 2020. [abstract] J Manag Care Pharm. 2020 Apr; 26(Supplement 4a):s58.
Allen LF, Aggarwal K, Vredenburg M, Barnett C, Mladsi D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 61st ASH American Society of Hematology Annual Meeting and Exposition; December 8, 2019. San Diego, CA. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):3454. doi: 10.1182/blood-2019-131822
Kurosky SK, Davis KL, Galindo CM. Effect of combination vaccines on hepatitis B vaccine compliance in children in the United States. Pediatr Infect Dis J. 2017 Jul;36(7):e189-96. doi: 10.1097/INF.0000000000001548
Mauskopf JA, Mitchell SE, Samuel M, Samp JC. Systematic literature review to identify cost estimates of liver disease in those with chronic hepatitis c virus (HCV) in the United States. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Mauskopf JA, Mitchell SE, Samuel M. Estimating costs in a cost-effectiveness analysis: adherence to HTA guidance. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014 Mar 6;9(3):e90295. doi: 10.1371/journal.pone.0090295
Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.
Younossi ZM, Gordon SC, Saab S, Ahmed A, Brogan A, Cure S. A decision-analytic Markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the American Association for the Study of Liver Diseases; November 1, 2013.
Younossi ZM, Saab S, Gordon SC, Ahmed A, Brogan A, Cure S. Evaluation of long-term health outcomes associated with earlier versus later initiation of treatment in previously untreated patients with chronic hepatitis C virus genotype 1 infection. Poster presented at the Annual Meeting of the American Association for the Study of Liver Diseases; November 1, 2013.
Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec;37(6):681-5. doi: 10.1111/j.1365-2710.2012.01371.x.
Brogan AJ, Talbird SE, Thompson J, Miller JD, George S, Hvidsten K. Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Presented at the 2012 Digestive Disease Week; May 2012.
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson JR. Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment. Poster presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Conference; November 2011. San Francisco, CA. [abstract] Hepatology. 2011 Oct 1; 54(Suppl. 1):802A-3A.
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson J. Cost-effectiveness assessment of telaprevir combination treatment compared to pegylated-interferon + ribavirin alone in the management of chronic hepatitis C in patients who failed a prior pegylated-interferon + ribavirin treatment. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 2011.
Brogan AJ, Miller JD, Talbird SE, Thompson J, Deniz B. Long-term clinical value of telaprevir for treatment of treatment-naïve and treatment-experienced patients with hepatitis C virus infection: projections using decision-analytic modeling. Poster presented at the 2011 Digestive Disease Week; May 9, 2011. Chicago, IL.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis c virus in a United States managed care population. J Clin Gastroenterol. 2011 Feb 1;45(2):e17-24.
Davis KL, Mitra D, Leteneux C, Bapat B, Naujoks C. Medical service utilization and costs by disease severity, sustained viral response, and genotype in European patients with chronic hepatitis c virus. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A71.
Davis KL, Mitra D, Leteneux C, Bapat B, Naujoks C. Utilization and cost of peginterferon plus ribavirin combination therapy in the management of chronic hepatitis c virus in Europe. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 1, 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A73-4.
Mitra D, Davis KL, Medjedovic J, Beam C, Rustgi V. The economic impact of medication non-adherence among managed care enrollees with chronic hepatitis C. Poster presented at the 21st Annual Meeting of the Academy of Managed Care Pharmacy; April 2009.
Mitra D, Candrilli SD. Inpatient costs and outcomes associated with hepatitis c, human immunodeficiency virus, and co-infection with both in the United States. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 8, 2008. [abstract] Value Health. 2008 Nov; 11(6):A440-1.
Mitra D, Davis KL, Medjedovic J, Beam C, Rustgi V. The economic burden of hcv and hbv co-infection: evidence from United States managed care data. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A440.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Variation in direct medical costs by disease severity among persons with chronic hepatitis c virus. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A335-6.
Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Economic burden of hcv and hiv co-infection compared to hcv alone in a managed care population. Poster presented at the Joint Meeting of the American Society for Microbiology and Infectious Disease Society of America; October 2008.
Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Association between sustained virologic response and health care costs in patients with chronic hepatitis C virus: evidence from a US managed care database. Poster presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 2008.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Real-world treatment patterns and medication costs in chronic hepatitis c: evidence from a US managed care database. Poster presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 2008.
Mitra D, Davis KL, Medjedovic J, Beam C, Rustgi VK. Health care utilization and costs associated with chronic hepatitis c in a managed care population. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A103.
Mitra D, Candrilli S, Davis KL, Bapat B. Inpatient costs and outcomes associated with chronic hepatitis c-related complications in the United States. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A107.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi VK. Direct economic burden of chronic hepatitis c virus in a large managed care population. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A87.
Rein DB, Hicks KA, Wirth KE, Billah K, Finelli L, Fiore AE, Hoerger TJ, Bell BP, Armstrong GL. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics. 2007 Jan 1;119(1):e12-21.
Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics. 2007 Jan 1;119(1):E22-9.
Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Economics of hepatitis A immunization. Presented at the U.S. Advisory Committee on Immunization Practices; June 2005. Atlanta, GA.
Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Update: economics of hepatitis A virus immunization. Presented at the ACIP Hepatitis Working Group; June 2005.
Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Results of RTI's cost-effectiveness evaluation of childhood hepatitis A vaccination strategies. Presented at the U.S. Advisory Committee on Immunization Practices (ACIP); June 2005. Atlanta, GA.